These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26666826)

  • 1. A novel therapeutic approach against B-cell non-Hodgkin's lymphoma through co-inhibition of Hedgehog signaling pathway and autophagy.
    Fan J; Zeng X; Li Y; Wang S; Yang P; Cao Z; Wang Z; Song P; Mei X; Ju D
    Tumour Biol; 2016 Jun; 37(6):7305-14. PubMed ID: 26666826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a potent hedgehog pathway inhibitor capable of activating caspase8-dependent apoptosis.
    Chen Q; Zhang H; Wu M; Wang Q; Luo L; Ma H; Zhang X; He S
    J Pharmacol Sci; 2018 Jul; 137(3):256-264. PubMed ID: 30064819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulating autophagy facilitated therapeutic efficacy of the sonic Hedgehog pathway inhibition on lung adenocarcinoma through GLI2 suppression and ROS production.
    Fan J; Zhang X; Wang S; Chen W; Li Y; Zeng X; Wang Y; Luan J; Li L; Wang Z; Sun X; Shen B; Ju D
    Cell Death Dis; 2019 Aug; 10(9):626. PubMed ID: 31427566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin's lymphoma tumor growth by promoting apoptosis and autophagy.
    Lv Y; Du Y; Li K; Ma X; Wang J; Du T; Ma Y; Teng Y; Tang W; Ma R; Wu J; Wu J; Feng J
    Cell Commun Signal; 2023 Jan; 21(1):16. PubMed ID: 36691066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the Hedgehog pathway induces autophagy in pancreatic ductal adenocarcinoma cells.
    Xu Y; An Y; Wang X; Zha W; Li X
    Oncol Rep; 2014 Feb; 31(2):707-12. PubMed ID: 24297612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
    Graab U; Hahn H; Fulda S
    Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vismodegib.
    Meiss F; Andrlová H; Zeiser R
    Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
    Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
    Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
    Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
    Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
    Ruiz Salas V; Alegre M; Garcés JR; Puig L
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel hedgehog inhibitor for the treatment of hematological malignancies.
    Lin P; He Y; Chen G; Ma H; Zheng J; Zhang Z; Cao B; Zhang H; Zhang X; Mao X
    Anticancer Drugs; 2018 Nov; 29(10):995-1003. PubMed ID: 30106753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog inhibitors: a patent review (2013 - present).
    Xin M
    Expert Opin Ther Pat; 2015 May; 25(5):549-65. PubMed ID: 25726713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Hedgehog signaling pathway impedes cancer cell proliferation by promotion of autophagy.
    Tang X; Deng L; Chen Q; Wang Y; Xu R; Shi C; Shao J; Hu G; Gao M; Rao H; Luo S; Lu Q
    Eur J Cell Biol; 2015 May; 94(5):223-33. PubMed ID: 25824057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
    De Smaele E; Ferretti E; Gulino A
    Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
    Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
    Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.
    Larsen AR; Bai RY; Chung JH; Borodovsky A; Rudin CM; Riggins GJ; Bunz F
    Mol Cancer Ther; 2015 Jan; 14(1):3-13. PubMed ID: 25376612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer.
    Ishii A; Shigemura K; Kitagawa K; Sung SY; Chen KC; Yi-Te C; Liu MC; Fujisawa M
    Anticancer Res; 2020 Sep; 40(9):5107-5114. PubMed ID: 32878799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
    Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
    Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.